Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Learn more about the event at www.virtualinvestorconferences.com.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

"Everything injected into the bloodstream is eventually ends up in the liver — that's just how our anatomy works," Professor ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2Planned workforce ...

Meanwhile, Dr. Manuel López-Figueroa and Dr. Carlos Buesa will remain on the Board, subject to a positive vote by the Shareholders’ Meeting.

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...

BOSTON and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical ...

Janux Therapeutics appointed Zachariah McIver to the role of chief medical officer. The San Diego-based biopharmaceutical company said Friday that McIver's expertise in T cell engagers ...

Indeed, it’s always surprised me a bit that San Diego doesn’t get mentioned more often as a top golf destination alongside hotbeds like Scottsdale, Ariz., and Myrtle Beach, S.C., where either ...